- mehrmals pro WocheErscheinungsrhythmus
- 17 mintypische Länge
- gesternletzte Folge
Scrip delivers expert-driven audio insight on biopharma — from R&D, commercial strategy and deal activity to coverage of major industry events. Every Monday, Ian Haydock presents Quick Listen: Five Must-Know Things, a weekly roundup of top industry stories. Joseph Haas hosts a quarterly deep-dive into dealmaking with guests from leading companies, law firms and investment firms. Visit insights.citeline.com/scrip to sign up. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.
Folgen
Rethinking Risk: Why Early Evidence Strategy Matters for Emerging Biotechs
For emerging biotech companies, development success is often measured by clinical milestones, safety, and efficacy. However, demonstrating an asset’s value extends beyond regulatory approval. Understanding patient needs and treatment experi
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast)
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月30日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括：美国《COINS法案》的影响；葛兰素史克（GSK）在肿瘤领域的业务转型；礼来（Lilly）在KRAS领域的推进；ris-rez为骨肉瘤治疗带来新希望；以及Genmab最新III期临床试验的胜利。 Story links here (https://insights.citeline.com/scrip/pod
Scrip's Five Must-Know Things: US COINS Impact, GSK's Oncology Turnaround, Lilly's KRAS Push
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.26, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月23日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括：欧洲肿瘤内科学会（ESMO）会议的关键预期；新一代抗体药物偶联物；冉冉升起的中盘股新星；葛兰素史克（GSK）新型乙肝药物的上市；以及私营企业的重大融资动态。 Story links here (https://insights.citeline.com/scrip/podcasts/scrips-five-m
Scrip's Five Must-Know Things: Key ESMO Readouts, Next-Gen ADCs And Mid-Cap Winners
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week
Scrip Awards Podcast – Parabilis CEO Mathai Mammen Interview
Ahead of the awards presentation on Dec 2, the Scrip Awards podcast speaks to Mathai Mammen, CEO of Parabilis, one of the shortlisted companies for Biotech of The Year.
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.19, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月16日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括：Tremfya从Stelara的余烬中崛起；辉瑞将成熟品牌作为试验田；中国科研力量在第三季度交易中大放异彩；Argenx在自身免疫领域取得进展与遭遇挫折；日本力图重振生物制药竞争力。 Story links: https://insights.citeline.com/scrip/podcasts/scrip
Scrip's Five Must-Know Things - Oct. 19, 2026
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week
Scrip's Five Must-Know Things - Oct. 13, 2026
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.14, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月9日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本周内容包括：中国带来的竞争威胁；第三季度并购活动降温；新型肺炎球菌疫苗竞争者；西班牙生物技术公司的战略；以及盐野义制药20亿美元的收购案。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-
Rethinking Success in Neuroscience Clinical Development
Despite significant scientific progress in neuroscience, clinical trial success rates remain low. Complex diseases, evolving therapeutic approaches and challenges around endpoint selection continue to make development difficult. As biomarke
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.5, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月2日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 谁在引领今年的并购步伐；罗氏（Roche）的研发管线重整；湿性黄斑变性（wet AMD）市场的洗牌；默克公司（Merck & Co.）撤回I-DXd申报；以及默克将Recarbio从市场上撤回。 Story links: https://insights.citeline.com/scrip/podcasts/s
Scrip's Five Must-Know Things - Oct. 5, 2026
Audio roundup of selected biopharma industry content from Scrip over the business week ended Oct. 2, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—who’s setting the M&A pace this year
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Sept. 25, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年9月25日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 中国带来的变革效应；诺和诺德的新战略；罗氏的抗肥胖新药；安进在舍格伦综合征治疗领域的胜利；以及中国潜在的重磅药物。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen
Scrip's Five Must-Know Things - Sept. 28, 2026
Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 25, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—China’s transforming effect; Novo’
Assessing the current dealmaking environment for psychedelic medicine.
Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways' COMP36
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Sept. 14, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年9月11日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 本期内容包括：近期III期试验失败后，心血管领域研发的下一步动向；全球销量前十的药物中有九款在第二季度实现连续增长；阿斯利康的首创性慢性阻塞性肺病（COPD）药物在III期试验中表现优于Dupixent；Renexxion联合创始人解析纳罗那普利为何能在胃轻瘫治疗中取得成功；以及中国企业在全球范围内的III期临床
Scrip's Five Must-Know Things - Sept, 14, 2026
Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 11, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—what’s next in cardiovascular R&D
中国药企2026年全球III期临床试验巡礼——从“单点突破”到“常态化出海” (Chinese-language podcast, Sept. 11, 2026)
根据Citeline旗下Scrip在2026年9月4日发布的最新统计，截至今年8月底，已经有六个由中国药企作为唯一申办方且在美国招募患者的全球III期临床试验启动。这个节奏已经追平了2025年全年的总量。今天我们就把这六个临床试验挨个拆开来看，再聊聊这背后代表的行业信号。 Story link: https://insights.citeline.com/scrip/r-and-d/clinical-trials/chinese-firms-start-six-global-
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Aug. 31, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月28日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 礼来研究显示Zepbound带来的成本节约可能超过其售价；罗氏达成最高23亿美元的韩美制药“肌肉保护型”减肥药交易；Revolution的Rasonque获美国批准用于治疗胰腺癌，Jazz的Ziihera获批用于治疗胃食管癌；以及梯瓦和维亚特里斯从仿制药转向创新药。 Story link: https://ins
Scrip's Five Must-Know Things - Aug. 31, 2026
Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 28, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Lilly study shows Zepbound's cost s
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Aug. 24, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月21日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Moderna的mRNA候选药物在黑色素瘤治疗方面取得突破；Enhertu在肺癌治疗方面取得胜利；衡量行业研发生产力；Enveda的GLP-1后继候选药物；以及中国崛起的背后因素。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-fi
Scrip's Five Must-Know Things - Aug. 24, 2026
Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 21, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—melanoma win for Moderna's mRNA can
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Aug. 17, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月14日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 全球特发性肺纤维化（IPF）研发管线概览；武田制药的嗜睡症药物获美国批准；Arrowhead公司探讨严重高甘油三酯血症治疗方案的差异化；SMID公司第二季度进展；以及Attruby在伴有心肌病变的转甲状腺素蛋白介导的淀粉样变性中的定位。 Story link: https://insights.citeline.
Scrip's Five Must-Know Things - Aug. 17, 2026
Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 14, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—a look at the global IPF pipeline;
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Aug. 10, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月7日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 诺和诺德考虑进行补充性收购；拜耳抨击德国定价政策；尽管Foundayo表现不佳，礼来股价仍大幅上涨；欧洲生物技术企业力求实现跨越式发展；以及对阿斯利康与百时美施贵宝在亚太地区潜在合并的展望。 Story link: https://insights.citeline.com/scrip/podcasts/scrip
Scrip's Five Must-Know Things - Aug. 10, 2026
Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 7, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Novo Nordisk weighs bolt-on deals; B
Podcast: China's Evolving Role in Global Clinical Development
China has become an increasingly important part of global clinical development, with sponsors considering the region earlier than ever before as part of their broader development strategies. In this episode, Meredith Landry, Managing Editor
